Form 4: Moderna Director Elizabeth Nabel Receives RSU Grant

Moderna Director Elizabeth Nabel was granted 8,371 restricted stock units as part of the company's equity compensation program.

Summary

• Director Elizabeth Nabel received a grant of 8,371 restricted stock units (RSUs) on May 6, 2026.
• The RSUs convert to common stock on a one-for-one basis.
• The award is subject to a vesting schedule tied to continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in minor potential future dilution for existing shareholders.

Risks

• Vesting is contingent upon the director's continued service to the company.

Future Outlook

The RSUs are scheduled to vest in full on May 6, 2027, or at the next Annual Meeting of Shareholders, whichever occurs first.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board alignment with long-term strategic goals.

Comparison to Industry Standards

• The grant of RSUs to directors is consistent with compensation practices at large-cap pharmaceutical and biotech firms like Pfizer, Amgen, and Gilead Sciences.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon the eventual vesting and conversion of the RSUs.

Next Steps

• Vesting of the RSU award on May 6, 2027, or the next Annual Meeting of Shareholders.

Key Dates

Keywords

Moderna, MRNA, Form 4, Insider Trading, Equity Compensation, Director Compensation